Literature DB >> 9662245

Pulmonary function after treatment for acute lymphoblastic leukaemia in childhood.

K Nysom1, K Holm, J H Olsen, H Hertz, B Hesse.   

Abstract

The aim of this study was to examine pulmonary function after acute lymphoblastic leukaemia in childhood and identify risk factors for reduced pulmonary function. We studied a population-based cohort of 94 survivors of acute lymphoblastic leukaemia in childhood who were in first remission after treatment without spinal irradiation or bone marrow transplantation. Pulmonary function test results were compared with reference values for our laboratory, based on 348 healthy subjects who had never smoked from a local population study. A median of 8 years after cessation of therapy (range 1-18 years) the participants had a slight, subclinical, restrictive ventilatory insufficiency and reduced transfer factor and transfer coefficient. The changes in lung function were related to younger age at treatment and to more dose-intensive treatment protocols that specified more use of cranial irradiation and higher cumulative doses of anthracyclines, cytosine arabinoside and intravenous cyclophosphamide than previous protocols. We conclude that, 8 years after treatment without bone marrow transplantation or spinal irradiation, survivors of childhood acute lymphoblastic leukaemia in first remission were without pulmonary symptoms but had signs of slight restrictive pulmonary disease including reduced transfer factor. The increased dose intensity of many recent protocols for childhood acute lymphoblastic leukaemia may lead to increased late pulmonary toxicity.

Entities:  

Mesh:

Year:  1998        PMID: 9662245      PMCID: PMC2062952          DOI: 10.1038/bjc.1998.436

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  The effects of cigarette smoking and smoking cessation on the carbon monoxide diffusing capacity of the lung in asymptomatic subjects.

Authors:  R J Knudson; W T Kaltenborn; B Burrows
Journal:  Am Rev Respir Dis       Date:  1989-09

2.  Pulmonary disease complicating intermittent therapy with methotrexate.

Authors:  A M Clarysse; W J Cathey; G E Cartwright; M M Wintrobe
Journal:  JAMA       Date:  1969-09-22       Impact factor: 56.272

3.  Lung function in white children aged 4 to 19 years: II--Single breath analysis and plethysmography.

Authors:  M Rosenthal; D Cramer; S H Bain; D Denison; A Bush; J O Warner
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

4.  Published models and local data can bridge the gap between reference values of lung function for children and adults.

Authors:  K Nysom; C S Ulrik; B Hesse; A Dirksen
Journal:  Eur Respir J       Date:  1997-07       Impact factor: 16.671

5.  Incidence of childhood cancer in Denmark 1943-1984.

Authors:  P de Nully Brown; H Hertz; J H Olsen; M Yssing; E Scheibel; O M Jensen
Journal:  Int J Epidemiol       Date:  1989-09       Impact factor: 7.196

6.  Pulmonary function in childhood leukaemia survivors.

Authors:  N J Shaw; P M Tweeddale; O B Eden
Journal:  Med Pediatr Oncol       Date:  1989

7.  Pulmonary function abnormalities in long-term survivors of childhood cancer.

Authors:  R W Miller; J E Fusner; R J Fink; T M Murphy; P R Getson; J A Vojtova; G H Reaman
Journal:  Med Pediatr Oncol       Date:  1986

8.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

Authors:  L J Steinherz; P G Steinherz; C T Tan; G Heller; M L Murphy
Journal:  JAMA       Date:  1991-09-25       Impact factor: 56.272

9.  Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia.

Authors:  P Shearer; J Katz; P Bozeman; J Jenkins; J Laver; R Krance; C Hurwitz; H Mahmoud; J Mirro
Journal:  Cancer       Date:  1994-10-01       Impact factor: 6.860

10.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

Authors:  S E Lipshultz; S D Colan; R D Gelber; A R Perez-Atayde; S E Sallan; S P Sanders
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

View more
  6 in total

Review 1.  Pulmonary outcomes in survivors of childhood cancer: a systematic review.

Authors:  Tseng-Tien Huang; Melissa M Hudson; Dennis C Stokes; Matthew J Krasin; Sheri L Spunt; Kirsten K Ness
Journal:  Chest       Date:  2011-03-17       Impact factor: 9.410

Review 2.  Surviving childhood cancer: the impact on life.

Authors:  Robert E Goldsby; Denah R Taggart; Arthur R Ablin
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation-a cohort study.

Authors:  Maria Otth; Christina Schindera; Tayfun Güngör; Marc Ansari; Katrin Scheinemann; Fabiën N Belle; Philipp Latzin; Nicolas von der Weid; Claudia E Kuehni
Journal:  Bone Marrow Transplant       Date:  2020-11-25       Impact factor: 5.483

4.  [Pulmonary function of children with acute leukemia in maintenance phase of chemotherapy].

Authors:  Thalita Medeiros Fernandes de Macêdo; Tania Fernandes Campos; Raquel Emanuele de França Mendes; Danielle Corrêa França; Gabriela Suéllen da Silva Chaves; Karla Morganna Pereira Pinto de Mendonça
Journal:  Rev Paul Pediatr       Date:  2014-12

5.  Long-term morbidity of respiratory viral infections during chemotherapy in children with leukaemia.

Authors:  Beryl Lin; Brendan Kennedy; Jamie McBride; Luciano Dalla-Pozza; Toby Trahair; Geoffrey McCowage; Emma Coward; Leanne Plush; Paul D Robinson; Kate Hardaker; John Widger; Anthea Ng; Adam Jaffe; Hiran Selvadurai
Journal:  Pediatr Pulmonol       Date:  2019-08-08

6.  Osteopathic Treatment and Evaluation in the Clinical Setting of Childhood Hematological Malignancies.

Authors:  Monica Barbieri; William Zardo; Chiara Frittoli; Clara Rivolta; Valeria Valdata; Federico Bouquin; Greta Passignani; Alberto Maggiani; Momcilo Jankovic; Andrea Cossio; Andrea Biondi; Adriana Balduzzi; Francesca Lanfranconi
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.